01Founding House
Kyal Agencies
Pharmaceutical Distribution
H. No. 362/A/3, Old College Lane, Nimchouri, Cuttack, Odisha — 753002
From a single trading house in Cuttack to a network of ten companies, Kyal Group moves medicine across eastern and western India — through wholesale distribution, carrying & forwarding, manufacturing and healthcare supply.
Kyal Group is a pharmaceutical distribution group with its origins in Cuttack, Odisha, where the family pharmaceutical trade began in the mid-1980s. What started as a single agency has grown, over four decades, into a network of ten companies operating across Odisha, West Bengal and Maharashtra.
The group's work sits along the trade channel of the pharmaceutical industry — receiving stock from manufacturers, holding it under proper conditions, and supplying it onward to pharmacies, hospitals and institutional buyers. Across distribution houses, carrying & forwarding operations, a research-led manufacturing company and a western-India healthcare arm, the companies share a common discipline: medicine handled with the care a regulated supply chain demands.
Each company is run by its own leadership and registered in its own right. Together they form a single group identity — Kyal Group — answerable to the same standard, batch after batch, year after year.
“A medicine is only as dependable as the chain that carries it. The chain is what we have spent forty years building.”
A complete directory of the companies that make up Kyal Group — each listed with its registered location, the person to reach, and a direct line. For trade enquiries, contact the company nearest the territory you serve.
Cuttack remains the founding base and the centre of group operations. From there, the network reaches the Odisha capital, the eastern metropolis of Kolkata, and the industrial belt of Navi Mumbai — three states, one chain of supply.
The Kyal family pharmaceutical trade takes root in Cuttack — a single agency supplying medicine to the local market.
Kyal Agencies Private Limited is incorporated under the Companies Act — CIN U51397OR2013PTC017154, RoC Cuttack — formalising the wholesale operation.
Kyal Agencies Universal Private Limited is registered — CIN U46497OD2024PTC045711 — extending the group into research-led pharmaceutical sciences.
Ten group companies operate across Odisha, West Bengal and Maharashtra — distribution, C&F, manufacturing and healthcare under one name.
Wholesale supply of pharmaceutical products to pharmacies, hospitals and institutional buyers — stock held under proper conditions and moved onward with batch-level traceability.
Stockpoint and C&F operations on behalf of pharmaceutical manufacturers — warehousing, order processing and onward dispatch into the regional trade.
Research-led pharmaceutical practice — formulation, manufacturing, regulatory affairs and quality control — bringing the group upstream of the trade counter.
The group's western-India arm — extending pharmaceutical supply and healthcare distribution into the Maharashtra market from Navi Mumbai.
Group-level enquiries, principal-manufacturer partnerships and trade correspondence are handled from the founding office in Cuttack. For a specific company, the direct line is listed against it in the Companies directory above.
Common enquiries from trade partners, manufacturers and visitors about how Kyal Group is structured and how to work with its companies.
Kyal Group is a pharmaceutical distribution group rooted in Cuttack, Odisha. It is the collective identity of ten companies operating across Odisha, West Bengal and Maharashtra — engaged in wholesale distribution, carrying & forwarding, research-led manufacturing and healthcare supply.
No. Kyal Group is a collective brand identity, not itself a single incorporated entity. Each member company is separately constituted, registered and operated in its own right. Any trade transaction is entered into with the specific member company concerned — not with "Kyal Group" as such.
The companies work along the pharmaceutical trade channel: receiving stock from manufacturers, holding it under proper conditions, and supplying it to pharmacies, hospitals and institutional buyers. Activities span wholesale distribution, carrying & forwarding (C&F) agency operations, research-led manufacturing through Kyal Agencies Universal, and healthcare distribution through the Navi Mumbai companies.
Contact the member company that serves your territory — every company is listed in the Companies directory with its address, contact person and a direct line. For group-level enquiries or principal-manufacturer partnerships, the founding office in Cuttack is the right first point of contact.
Trade orders are placed directly with the relevant member company. Onboarding requires valid drug-licence documentation and applicable statutory registrations; once verified, orders are fulfilled against confirmed stock with batch-level traceability on each invoice.
No. The group's companies operate on a business-to-business basis. Patients should obtain Kyal-supplied medicines from their licensed pharmacy or treating hospital, on a valid prescription where required by law.
The founding base and centre of group operations is Cuttack, Odisha. The wider network reaches Bhubaneswar, Kolkata in West Bengal, and Navi Mumbai in Maharashtra — four cities across three states.
Each member company operates under the drug-licensing and good-practice requirements applicable to its activity, with stock held and handled to preserve product integrity — including cold-chain conditions where a product requires them. Kyal Agencies Universal additionally maintains the manufacturing and quality-control practices appropriate to a research-led pharmaceutical company.
Product complaints, batch-quality concerns or suspected adverse events should be raised with the member company that supplied the goods, by phone or WhatsApp on the number listed against it. Reports are logged, triaged and, where serious, escalated within applicable statutory timeframes.
The policies below set out how Kyal Group and its member companies handle information, trade, returns and dispatch. Because the group is a collective of independently constituted companies, a specific transaction is governed by the terms of the member company concerned, read together with these group documents.
This policy describes how Kyal Group and its member companies (together, the group, we, our) collect, use, retain and protect personal and business information of trade partners, manufacturers, clinicians and visitors interacting with the group through trade dealings, telephone and WhatsApp correspondence, and any digital channels operated by the group or its companies.
We collect: (a) identity and contact information — name, designation, organisation, business address, telephone, email and statutory identifiers such as GSTIN and drug-licence number; (b) commercial information — order history, invoices, payment references and delivery acknowledgements; (c) technical information from electronic communication, including device and timestamp metadata where applicable; and (d) information voluntarily reported in connection with a product complaint or suspected adverse drug reaction.
Information is processed on the lawful bases of contract performance, statutory obligation under Indian pharmaceutical and tax law, and legitimate business interest in operating a regulated supply chain. Purposes include order fulfilment, invoicing, drug-licence verification, regulatory reporting, audit compliance, and protection against fraud or product diversion.
We share information with: statutory and regulatory authorities where disclosure is required by law; other member companies of the group strictly where needed to serve a request; authorised distribution, logistics and payment partners; and professional advisers under confidentiality obligation. We do not sell personal information.
Information is retained for the period required to satisfy the purposes above and to comply with record-keeping obligations under the Companies Act, the GST regime and the Drugs and Cosmetics Act. On expiry of that period, records are securely deleted or anonymised.
We apply administrative, technical and physical safeguards proportionate to the sensitivity of the data, including access control and incident-response procedures. No transmission method is perfectly secure; counterparties are asked to apply equivalent diligence on their side.
Subject to applicable law, you may request access to, correction of, or deletion of personal information held about you, by contacting the relevant member company or the group office at Cuttack. We respond within statutory timeframes, subject to identity verification and any overriding record-keeping obligation.
This policy may be updated from time to time; the current version is the one published here. It is governed by Indian law, and the courts at Cuttack, Odisha have exclusive jurisdiction over any dispute arising in connection with it.
'Group' means Kyal Group, the collective identity of the Kyal pharmaceutical companies. 'Member Company' means any one of the companies listed in the Companies directory. 'Counterparty', 'you' means any person or entity engaging with the group or a member company. 'Goods' means pharmaceutical products supplied by a member company.
Kyal Group is a collective brand identity and is not itself a single incorporated legal entity. Each member company is separately constituted and contracts in its own name. Reference to "the group" is descriptive and does not create joint or several liability among member companies. Every trade transaction is with the specific member company concerned.
This website is provided for general informational purposes. Content — including addresses, contact persons and statutory identifiers — is published in good faith and believed accurate at the time of publication, but may change without notice.
Trade orders may be placed only by entities holding a valid drug licence and applicable statutory registrations, and are placed with the relevant member company. An order constitutes an offer to purchase; acceptance occurs on dispatch confirmation, until which point the member company may decline an order in whole or in part.
Prices are exclusive of taxes unless stated; applicable GST is charged on every invoice. Payment is due against the terms communicated at order acceptance. Outstanding amounts beyond the agreed period may attract interest, suspension of further dispatch, and recovery proceedings under applicable law.
The counterparty undertakes to handle, store, dispense and resell the Goods in compliance with the Drugs and Cosmetics Act and applicable rules, including cold-chain requirements where stated, and shall maintain records sufficient for batch traceability.
All trademarks, the Kyal name and brand elements, product literature and digital assets remain the exclusive property of the group or the relevant member company. Reproduction or commercial reuse without prior written consent is prohibited.
Subject to applicable law, a member company's aggregate liability arising out of any single order shall not exceed the invoice value of that order. No member company shall be liable for indirect, incidental or consequential damages, except where such limitation is excluded by mandatory statute.
No party is liable for delay or failure caused by events outside reasonable control — natural disaster, public-health emergency, regulatory action, transport disruption or supply-chain failure — provided notice is given and reasonable mitigation undertaken.
These terms are governed by the laws of India. The courts at Cuttack, Odisha have exclusive jurisdiction over any dispute arising in connection with them or any transaction governed by them.
As regulated pharmaceutical suppliers, the member companies do not accept returns of correctly supplied Goods on grounds of changed buying preference. Returns are limited to the scenarios below and are subject to verification.
A return is processed by the member company that supplied the Goods, identified on the relevant tax invoice. The contact details of every company are in the Companies directory.
Returns are eligible where: (a) Goods were supplied in error against the confirmed order; (b) Goods were damaged in transit and the damage was recorded on the proof of delivery; (c) Goods were received with a manufacturing defect or short shelf-life inconsistent with the order; or (d) a regulatory recall has been initiated.
Discrepancies under heads (a) and (b) must be notified within seven (7) calendar days of receipt with photographic evidence and the original delivery acknowledgement. Defects under head (c) must be notified within thirty (30) calendar days of receipt, or within seven (7) days of detection where the defect could not reasonably have been found earlier.
Returned Goods must be in original primary and secondary packaging, with intact batch and expiry information, free of any tampering or relabelling, and accompanied by the relevant invoice number and a signed return authorisation issued by the member company.
Cold-chain products are accepted for return only where temperature integrity throughout the chain can be evidenced by data logger or equivalent record. A cold-chain breach disqualifies a return regardless of physical condition.
Approved returns are credited against future invoices, or refunded to the originating bank account at the member company's discretion, within fourteen (14) working days of acceptance of the returned consignment. GST adjustments are processed through a compliant credit note.
Member companies dispatch Goods to verified trade addresses where the counterparty holds a valid drug licence and where the company is in a position to serve under prevailing logistics and regulatory conditions. Service to a particular location is confirmed at order acceptance.
Confirmed orders are typically picked, packed and dispatched within two (2) to four (4) working days of acceptance, subject to product availability and successful drug-licence verification. Cold-chain consignments may follow a separate dispatch cadence.
Dispatch is undertaken through logistics partners selected for pharmaceutical handling capability and, where applicable, cold-chain qualification. Tracking references, where issued by the carrier, are shared with the counterparty's nominated contact.
Temperature-sensitive Goods are dispatched in qualified shipper systems with data loggers as required by product label. The counterparty is asked to inspect the logger record on receipt; any excursion must be flagged before unpacking and stocking.
On delivery, the counterparty's representative must inspect the consignment for parcel count and visible damage and record any discrepancy on the proof of delivery. Acceptance without such notation is treated as acknowledgement of correct delivery.
Logistics charges, where applicable, are stated at order acceptance and itemised on the invoice. Where delivery cannot be completed because the consignee is unavailable or refuses receipt, Goods are returned to the nearest hub; re-dispatch attracts further charges, and short-shelf-life Goods may be quarantined.
"Kyal Group" describes a family of independently constituted companies under common association and management. It is not a single incorporated entity, and reference to "the group" on this website does not create joint liability among the member companies or imply a single legal personality.
Information on this website is provided for general informational purposes. Addresses, contact persons and other particulars are believed accurate at the time of publication and may change; the relevant member company should be contacted to confirm current details.
Corporate Identification Numbers (CIN) and GST identifiers shown on this site are drawn from publicly available records. For authoritative confirmation, refer to the Ministry of Corporate Affairs and the GST portal. Where statutory data is not shown for a company, it has simply been omitted rather than represented.
Nothing on this website constitutes medical, legal, tax or other professional advice. Medicines should be obtained and used only through licensed channels and qualified professionals.
Where this site links to external resources, those resources are not under the group's control and the group accepts no responsibility for their content or availability.